Proteins and their derived peptides as carriers in a conjugate vaccine for Streptococcus pneumoniae: Self-heat shock protein 60 and tetanus toxoid

Journal of Immunology

Volumn 170, Issue 12, 2003, Pages 6165-6171

  Amir Kroll, Hila ^a   Nussbaum, Gabriel ^a   Cohen, Irun R ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL POLYSACCHARIDE; CAPSULAR POLYSACCHARIDE 4; CARRIER PROTEIN; EPITOPE; HEAT SHOCK PROTEIN 60; IMMUNOGLOBULIN G; PEPTIDE; STREPTOCOCCUS VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; BACTERIAL STRAIN; DRUG CONJUGATION; DRUG EFFICACY; FEMALE; GENOTYPE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTECTION; STATISTICAL SIGNIFICANCE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; T LYMPHOCYTE; TREATMENT OUTCOME; VACCINATION;

EID: 0037604808     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.12.6165     Document Type: Article

References (44)

1. Konen-Waisman, S., M. Fridkin, and I. R. Cohen. 1995. Self and foreign 60-kilodalton heat shock protein T cell epitope peptides serve as immunogenic carriers for a T cell-independent sugar antigen. J. Immunol. 154:5977.
2. Konen-Waisman, S., A. Cohen, M. Fridkin, and I. R. Cohen. 1999. Self heat-shock protein (hsp60) peptide serves in a conjugate vaccine against a lethal pneumococcal infection. J. Infect. Dis. 179:403.
3. Heath, P. T. 1998. Haemophilus influenzae type b conjugate vaccines: a review of efficacy data. Pediatr. Infect. Dis. J. 17:S117.
4. Nurkka, A., H. Ahman, M. Yaich, J. Eskola, and H. Kayhty. 2001. Serum and salivary anti-capsular antibodies in infants and children vaccinated with octavalent pneumococcal conjugate vaccines, PncD and PncT. Vaccine 20:194.
5. Wuorimaa, T., R. Dagan, M. Vakevainen, F. Bailleux, R. Haikala, M. Yaich, J. Eskola, and H. Kayhty. 2001. Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant. J. Infect. Dis. 184:1211.
6. Dagan, R., M. Sikuler-Cohen, O. Zamir, J. Janco, N. Givon-Lavi, and D. Fraser. 2001. Effect of a conjugate pneumococcal vaccine on the occurrence of respiratory infections and antibiotic use in day-care center attendees. Pediatr. Infect. Dis. J. 20:951.
7. Wuorimaa, T., H. Kayhty, O. Leroy, and J. Eskola. 2001. Tolerability and immunogenicity of an 11-valent pneumococcal conjugate vaccine in adults. Vaccine 19:1863.
8. Panina-Bordignon, P., A. Tan, A. Termijtelen, S. Demotz, G. Corradin, and A. Lanzavecchia. 1989. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur. J. Immunol. 19:2237.
9. Valmori, D., A. Pessi, E. Bianchi, and G. Corradin. 1992. Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination. J. Immunol. 149:717.
10. Keitel, W. A., K. E. Kester, R. L. Atmar, A. C. White, N. H. Bond, C. A. Holland, U. Krzych, D. R. Palmer, A. Egan, C. Diggs, et al. 1999. Phase I trial of two recombinant vaccines containing the 19 kD carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid. Vaccine 18:531.
11. + T cell-targeted vaccine restimulates the memory CD4 T cell response but fails to induce cytotoxic T lymphocytes (CTL). Clin. Exp. Immunol. 105:18.
12. Slingluff, C. L., Jr., G. Yamshchikov, P. Neese, H. Galavotti, S. Eastham, V. H. Engelhard, D. Kittlesen, D. Deacon, S. Hibbitts, W. W. Grosh, et al. 2001. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin. Cancer Res. 7:3012.
13. Moudgil, K. D., S. Southwood, A. Ametani, K. Kim, A. Sette, and E. E. Sercarz. 1999. The self-directed T cell repertoire against mouse lysozyme reflects the influence of the hierarchy of its own determinants and can be engaged by a foreign lysozyme. J. Immunol. 163:4232.
14. Elias, D., T. Reshef, O. S. Birk, R. van der Zee, M. D. Walker, and I. R. Cohen. 1991. Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein. Proc. Natl. Acad. Sci. USA 88:3088.
15. Dubois, M., K. Gilles, J. Hamilton, P. Rebers, and F. Smith. 1956. Colorimetric method for determination of sugars and related substances. Anal. Chem. 28:350.
16. Kruger, N. J. 1994. The Bradford method for protein quantitation. Methods Mol. Biol. 32:9.
17. Fattom, A., X. Li, Y. H. Cho, A. Burns, A. Hawwari, S. E. Shepherd, R. Coughlin, S. Winston, and R. Naso. 1995. Effect of conjugation methodology, carrier protein, and adjuvants on the immune response to Staphylococcus aureus capsular polysaccharides. Vaccine 13:1288.
18. + T cell epitopes provide help to Haemophilus influenzae type b oligosaccharide: a model for new conjugate vaccines. Eur. J. Immunol. 31:3816.
19. Peeters, C. C., A. M. Tenbergen-Meekes, J. T. Poolman, M. Beurret, B. J. Zegers, and G. T. Rijkers. 1991. Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines. Infect. Immun. 59:3504.
20. van den Dobbelsteen, G. P., and E. P. van Rees. 1995. Mucosal immune responses to pneumococcal polysaccharides: implications for vaccination. Trends Microbiol. 3:155.
21. Peeters, C. C., A. M. Tenbergen-Meekes, D. E. Evenberg, J. T. Poolman, B. J. Zegers, and G. T. Rijkers. 1991. A comparative study of the immunogenicity of pneumococcal type 4 polysaccharide and oligosaccharide tetanus toxoid conjugates in adult mice. J. Immunol. 146:4308.
22. Eskola, J. 2000. Immunogenicity of pneumococcal conjugate vaccines. Pediatr. Infect. Dis. J. 19:388.
23. Valmori, D., A. Sabbatini, A. Lanzavecchia, G. Corradin, and P. M. Matricardi. 1994. Functional analysis of two tetanus toxin universal T cell epitopes in their interaction with DR1101 and DR1104 alleles. J. Immunol. 152:2921.
24. Goldblatt, D. 2000. Conjugate vaccines. Clin. Exp. Immunol. 119:1.
25. Audibert, F., and L. Chedid. 1984. Of antigens, adjuvants and carriers in synthetic vaccines. Cold Spring Harbor Laboratory, New York.
26. Schutze, M. P., C. Leclerc, M. Jolivet, F. Audibert, and L. Chedid. 1985. Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. J. Immunol. 135:2319.
27. Herzenberg, L. A., and T. Tokuhisa. 1982. Epitope-specific regulation. I. Carrier-specific induction of suppression for IgG anti-hapten antibody responses. J. Exp. Med. 155:1730.
28. Lett, E., S. Gangloff, M. Zimmermann. D. Wachsmann, and J. P. Klein. 1994. Immunogenicity of polysaccharides conjugated to peptides containing T- and B-cell epitopes. Infect. Immun. 62:785.
29. Del Giudice, G. 1992. New carriers and adjuvants in the development of vaccines. Curr. Opin. Immunol. 4:454.
30. Dagan, R., J. Eskola, C. Leclerc, and O. Leroy. 1998. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect. Immun. 66:2093.
31. Ahman, H., H. Kayhty, A. Vuorela, O. Leroy, and J. Eskola. 1999. Dose dependency of antibody response in infants and children to pneumococcal polysaccharides conjugated to tetanus toxoid. Vaccine 17:2726.
32. Bell, F., P. Health, F. Shackley, J. Maclennan, M. Herbert, N. Shearstone, L. Diggle, E. R. Moxon, and A. Finn. 1999. Poor response to hib (PRP-T) vaccine when combined with an acellular pertussis/diphtheria/tetanus vaccine for primary immunization of infants. Biologicals 27:113.
33. Gupta, R. K., R. Anderson, D. Cecchini, B. Rost, J. Xu, K. Gendreau, D. L. Saroff, C. Marchant, and G. R. Siber. 1999. Evaluation of a guinea pig model to assess interference in the immunogenicity of different components of a combination vaccine comprising diphtheria, tetanus and acellular pertussis (DTaP) vaccine and Haemophilus influenzae type b capsular polysaccharide conjugate vaccine. Biologicals 27:167.
34. Fattom, A., Y. H. Cho, C. Chu, S. Fuller, L. Fries, and R. Naso. 1999. Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines. Vaccine 17:126.
35. Alexander, J., J. Sidney, S. Southwood, J. Ruppert, C. Oseroff, A. Maewal, K. Snoke, H. M. Serra, R. T. Kubo, A. Sette, et al. 1994. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1:751.
36. Alexander, J., M. F. del Guercio, A. Maewal, L. Qiao, J. Fikes, R. W. Chesnut, J. Paulson, D. R. Bundle, S. DeFrees, and A. Sette. 2000. Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses. J. Immunol. 164:1625.
37. Usinger, W. R., and A. H. Lucas. 1999. Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides. Infect. Immun. 67:2366.
38. Chen, W., U. Syldath, K. Bellmann, V. Burkart, and H. Kolb. 1999. Human 60-kDa heat-shock protein: a danger signal to the innate immune system. J. Immunol. 162:3212.
39. Cohen, I. R., and D. B. Young. 1991. Autoimmunity, microbial immunity and the immunological homunculus. Immunol. Today 12:105.
40. Cohen, I. R. 1991. Autoimmunity to chaperonins in the pathogenesis of arthritis and diabetes. Annu. Rev. Immunol. 9:567.
41. Quintana, F. J., and I. R. Cohen, 2001. Autoantibody patterns in diabetes-prone NOD mice and in standard C57BL/6 mice. J. Autoimmun. 17:191.
42. Garg, M., W. Luo, A. M. Kaplan, and S. Bondada. 1996. Cellular basis of decreased immune responses to pneumococcal vaccines in aged mice. Infect. Immun. 64:4456.
43. Sankilampi, U., P. O. Honkanen, R. Pyhala, and M. Leinonen, 1997. Associations of prevaccination antibody levels with adverse reactions to pneumococcal and influenza vaccines administered simultaneously in the elderly. Vaccine 15:1133.
44. Rubins, J. B., and E. N. Janoff. 2001. Pneumococcal disease in the elderly: what is preventing vaccine efficacy? Drugs Aging 18:305.